Abstract
Failure of conventional as well as target-based therapy against the advanced metastatic cancers is a significant clinical problem. While some cancers, such as pancreatic cancer, respond poorly to any kind of therapies, tumor relapse is often observed in many other cancer types after initial therapeutic response. Hence, significant research is being conducted to understand the mechanisms underlying therapeutic refractoriness of cancer. During the past decade, cancer stem cell (CSC) hypothesis has gained significant experimental and clinical support, and CSCs have emerged as potentially useful pharmacologic targets. MicroRNAs (miRNAs) are a group of small (~18–25 nucleotides) non-protein encoding RNAs that are now established as important regulators of gene expression. They can function as tumor promoters (oncomirs) or suppressors (anti-oncomirs) and thus hold profound implications for cancer therapy. Recent studies have identified several miRNAs to be differentially expressed in CSCs and established their role in targeting genes and pathways supporting cancer stemness properties. Here, we discuss these findings and review recent advances in miRNA-based strategies to exploit therapeutic potential of miRNAs in cancer treatment.
Keywords: Cancer stem cells, cellular mechanisms, MicroRNAs, pancreatic cancer, stemness, therapeutics.
Current Drug Targets
Title:Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Volume: 14 Issue: 10
Author(s): Arun Bhardwaj, Sumit Arora, Vijay K. Prajapati, Seema Singh and Ajay P. Singh
Affiliation:
Keywords: Cancer stem cells, cellular mechanisms, MicroRNAs, pancreatic cancer, stemness, therapeutics.
Abstract: Failure of conventional as well as target-based therapy against the advanced metastatic cancers is a significant clinical problem. While some cancers, such as pancreatic cancer, respond poorly to any kind of therapies, tumor relapse is often observed in many other cancer types after initial therapeutic response. Hence, significant research is being conducted to understand the mechanisms underlying therapeutic refractoriness of cancer. During the past decade, cancer stem cell (CSC) hypothesis has gained significant experimental and clinical support, and CSCs have emerged as potentially useful pharmacologic targets. MicroRNAs (miRNAs) are a group of small (~18–25 nucleotides) non-protein encoding RNAs that are now established as important regulators of gene expression. They can function as tumor promoters (oncomirs) or suppressors (anti-oncomirs) and thus hold profound implications for cancer therapy. Recent studies have identified several miRNAs to be differentially expressed in CSCs and established their role in targeting genes and pathways supporting cancer stemness properties. Here, we discuss these findings and review recent advances in miRNA-based strategies to exploit therapeutic potential of miRNAs in cancer treatment.
Export Options
About this article
Cite this article as:
Bhardwaj Arun, Arora Sumit, Prajapati K. Vijay, Singh Seema and Singh P. Ajay, Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential, Current Drug Targets 2013; 14 (10) . https://dx.doi.org/10.2174/13894501113149990190
DOI https://dx.doi.org/10.2174/13894501113149990190 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Current Pharmaceutical Design RNA Splicing: Basic Aspects Underlie Antitumor Targeting
Recent Patents on Anti-Cancer Drug Discovery Distinct Epigenetic Reprogramming, Mitochondrial Patterns, Cellular Morphology, and Cytotoxicity after Bee Venom Treatment
Recent Patents on Anti-Cancer Drug Discovery Radiogenetic Therapy: Strategies to Overcome Tumor Resistance
Current Pharmaceutical Design Epigenetic Effects of Cadmium in Cancer: Focus on Melanoma
Current Genomics Nuclear Hormone Receptor Signals as New Therapeutic Targets for Urothelial Carcinoma
Current Cancer Drug Targets Anti-Inflammatory Iridoids of Botanical Origin
Current Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Current Uses of Robotic Surgery for the Treatment of Benign Adnexal Conditions
Current Women`s Health Reviews Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Heparanase: Structure, Biological Functions, and Inhibition by Heparin-Derived Mimetics of Heparan Sulfate
Current Pharmaceutical Design Modulation of k-Ras Signaling by Natural Products
Current Medicinal Chemistry Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design Recent Patents Review in Three Dimensional Ultrasound Imaging
Recent Patents on Biomedical Engineering (Discontinued) Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening E2F1-Mediated Apoptosis as a Target of Cancer Therapy
Current Molecular Pharmacology Majra Honey Abrogated the Normal and Cancer Cells Proliferation Inhibition by Juniperus procera Extract and Extract/Honey Generated AgNPs
Anti-Cancer Agents in Medicinal Chemistry The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Current Pharmaceutical Design